ProCE Banner Activity

Immune Checkpoint Inhibition and Targeted Therapy in Early TNBC

Slideset Download
Get up to date on current and emerging perioperative treatment options for patients with early TNBC.

Released: December 07, 2022

Expiration: December 06, 2023

Share

Faculty

Melinda Telli

Melinda Telli, MD

Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

AstraZeneca Pharmaceuticals

Lilly

Merck Sharp & Dohme, LLC

Sanofi

Faculty Disclosure

Primary Author

Melinda Telli, MD

Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California